Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb trial of ONY-P vaccines in non-metastatic hormone-escape prostate cancer
2006-001619-31Phase 2Completed
- Sponsor
- Onyvax
- Start
- Mar 2006
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of Prostate cancer vaccine ONY-P1 and ONY-P2 in prostate cancer (PCa) (2 arms), sponsored by Onyvax. Primary endpoints: Progression-free survival at 12 months, Duration of progression-free survival and 1 more. Started Mar 2006; status: completed.
02
Drugs
Prostate cancer vaccine ONY-P1ONY-P2
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-001619-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001619-31.